{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Intellia Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"NTLA"},"Address":{"label":"Address","value":"40 ERIE STREET,SUITE 130, CAMBRIDGE, Massachusetts, 02139, United States"},"Phone":{"label":"Phone","value":"+1 857 285-6200"},"Industry":{"label":"Industry","value":"Biotechnology: In Vitro & In Vivo Diagnostic Substances"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis."},"CompanyUrl":{"label":"Company Url","value":"https://www.intelliatx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David Lebwohl","title":"Chief Medical Officer & Executive Vice President"},{"name":"Eliana Clark","title":"Chief Technology Officer & Executive VP"},{"name":"John M. Leonard","title":"President, Chief Executive Officer & Director"},{"name":"Laura Sepp-Lorenzino","title":"Chief Scientific Officer & Executive VP"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}